SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...
Vir Biotechnology Inc (NASDAQ:VIR) completed enrollment in Eclipse One, their first registrational phase 3 study for hepatitis Delta, ahead of schedule. The company plans to share a comprehensive data ...
SAN FRANCISCO, November 03, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy ...
The Central Government has released a gazette notification listing gallantry award citations for defence personnel from multiple operations, including Operation Sindoor. The citations highlight acts ...
– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical ...
– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to ...
Marianne De Backer, PhD, MBA, CEO of Vir Biotechnology, has led the company's pivot to focusing on cancer as well as infectious diseases. [Vir Biotechnology] Between launching clinical studies for its ...
Hosted on MSN
Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation
Fintel reports that on July 11, 2025, Raymond James initiated coverage of Vir Biotechnology (NasdaqGS:VIR) with a Outperform recommendation. Analyst Price Forecast Suggests 232.11% Upside As of June ...
A.I. has yet to upend Hollywood. But it is starting to make big inroads in animation. The founders of Toonstar, a small animation studio in downtown Los Angeles, have incorporated A.I. at various ...
- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME ...
- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback